Home
Company
Core
Product
International Market
News
Contact Us
Related links
language
About Us
NEXTEYE Group
NEXTEYE was founded on September 29, 1998, initially focusing on the research and manufacturing of industrial automation testing equipment, serving Samsung LG、 Hyundai and other Korean giants provided key technological support and successfully listed on the Korean Growth Enterprise Market, becoming industry leaders. After receiving strategic investments from top Korean venture capital firms such as AJUIB and Aesthetic International, the company aggressively entered the biotechnology and beauty industries in the 2010s. Under the leadership of Ms. Sunny Chen, the chairman of the board of directors, the company has completed a series of important layout: investing in the merger and acquisition of cosmetics manufacturing enterprises NEW&NEW, INS KOREA (the largest nail polish factory in South Korea) and plastic surgery hospital SYMPHONY; Establish a subsidiary JDML Cosmetic, and launch popular online red products (such as VN sunscreen, FHD blood orange facial mask) in the Chinese and Korean markets; Establishing a biological laboratory led by Harvard expert Dr. Hongbing Zhang in the United States through subsidiary NEXTONE Bio; Invest in PRP SCIENCE, which has exclusive permission for subcutaneous injection of hyaluronic acid in Asia. Subsidiary INNOMETRY has successfully gone public. In 2025, NEXTEYE accelerates its globalization process: NEXTSTAR CHINA, a cross-border e-commerce company established by NEXTONE in Shenzhen, China, and a global operational headquarters established in Sha Tin, Hong Kong. Its self operated cross-border e-commerce platform was officially launched in June of the same year, marking the company's entry into a new era of global e-commerce.

AESTHETIC, a cosmetics factory in Shenzhen, China

Covering an area of approximately 10000 square meters; 3 semi-automatic production lines; Annual output of up to 60 million units; Environmental pollution discharge reaches the highest level in the country; A production workshop with a purification level of 100000; Obtained ISO 9001 and ISO 22716 certifications; Obtained EU GMP international production standard certification; Obtained FDA International Production Practice Certification from the US Food and Drug Administration

California Biotechnology R&D Team

The GeneAKG anti-aging and longevity technology, led by Dr. Hongbing Zhang, CEO of NEXTSTAR Biotechnology and a team of scientists from Harvard Medical University, is at the core of the technology! The world's first collagen nanomembrane weaving technology by HUITI, a light medical beauty technology; Discovering the role and mechanism of metabolic abnormalities in liver cancer cells and proposing targeted therapy directions: β - catenin, AKT2, and pyrimidine synthesis inhibitors are the most effective therapies for treating carcinogenic β - catenin related cancers

About Us
NextStar is a wholly-owned subsidiary of NEXTEYE Co., LTD, a South Korean listed company, invested and established in Shenzhen, with its operational headquarters located in Sha Tin District, Hong Kong. As a global cross-border e-commerce platform, its main business scope is extensive, covering categories such as cosmetics, general and health foods, and daily necessities. With the strong strength and resources of its parent company, Future Star is committed to providing consumers with diverse and high-quality products, building convenient cross-border shopping bridges, constantly exploring and advancing in the field of cross-border e-commerce, and providing a better shopping platform for global consumers.
Contact Us
Phone: 400-900-7000
Address: 201, Building A6, Life Science Industrial Park, No. 142 Jinye Avenue, Sanxi Community, Kwai Chung Street, Dapeng New District, Shenzhen
Record number: Guangdong ICP No. 2025429504-2
Guangdong Public Security Registration No. 44030002007579
Email: service@nextstarbio.com
Powered by Feedback Manage